Search - tctmd.com

Displaying 201 - 220 of 289

Sort: Relevancy | Date

Presentation TCT 2012

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

Presenter: Fabio Mangiacapra

October 23, 2012

News Daily News

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Jason Kahn

October 19, 2012

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

News Daily News

In Transradial PCI, Bivalirudin Fails to Budge Event Rates vs. Heparin

October 12, 2012

News Daily News

En la PCI Transradial, comparada con la Heparina, la Bivalirudina No Altera los Índices de Episodios

October 12, 2012

News Daily News

La Dosis de Carga Doble de Clopidogrel No Ofrece Beneficio Alguno en Pacientes con ERC que se someten a PCI Primarias

L.A. McKeown

September 18, 2012

News Daily News

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

L.A. McKeown

September 18, 2012

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

Presentation ESC 2012

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

Presenter: 159942|Jolanta Siller-Matula

August 26, 2012

News Daily News

Timing of Platelet Testing Key to Optimal Therapy After PCI for ACS

L.A. McKeown

August 20, 2012

News Daily News

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

L.A. McKeown

August 01, 2012

News Daily News

Stopping Clopidogrel 1 Year After MI Raises Risk in PCI Patients

Jason Kahn

July 20, 2012

News Daily News

Meta-analysis: Adjusting Therapy Based on Platelet Function Results Improves Outcomes

July 12, 2012

News Daily News

Meta Análisis: Ajustar el Tratamiento según la Función Plaquetaria Mejora los Resultados

July 12, 2012

News Daily News

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

July 10, 2012

News Daily News

El Ticagrelor ofrece una Inhibición Plaquetaria Más Potente que el Prasugrel

July 10, 2012

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Daily News

HORIZONS-AMI: Resultados Similares con Abciximab y Eptifibatide durante PCI Primaria

July 05, 2012

News Daily News

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Caitlin E. Cox

June 07, 2012

News Daily News

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

June 05, 2012

Advertisement

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

In Transradial PCI, Bivalirudin Fails to Budge Event Rates vs. Heparin

En la PCI Transradial, comparada con la Heparina, la Bivalirudina No Altera los Índices de Episodios

La Dosis de Carga Doble de Clopidogrel No Ofrece Beneficio Alguno en Pacientes con ERC que se someten a PCI Primarias

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

Timing of Platelet Testing Key to Optimal Therapy After PCI for ACS

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

Stopping Clopidogrel 1 Year After MI Raises Risk in PCI Patients

Meta-analysis: Adjusting Therapy Based on Platelet Function Results Improves Outcomes

Meta Análisis: Ajustar el Tratamiento según la Función Plaquetaria Mejora los Resultados

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

El Ticagrelor ofrece una Inhibición Plaquetaria Más Potente que el Prasugrel

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

HORIZONS-AMI: Resultados Similares con Abciximab y Eptifibatide durante PCI Primaria

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content